January 6, 2017
Sanofi, Regeneron to appeal on Praluent ban in the U.S. due to two Amgen patents
Sanofi and Regeneron Pharmaceuticals are going to will appeal the injunction granted on Friday by the U.S. District Court for the District of Delaware preventing the marketing, selling or manufacturing of Praluent in the U.S. during the term of two Amgen patents.